Pharmaceutical

Biothera Pharmaceuticals Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca

Collaboration will evaluate the combination of Biothera’s Imprime PGG and AstraZeneca’s durvalumab in a Phase 2 neoadjuvant study for patients with head and neck cancer EAGAN, MN — September 5, 2018 — Biothera Pharmaceuticals, Inc. announced today a clinical collaboration with AstraZeneca to evaluate whether the combination of Biothera’s Imprime PGG and AstraZeneca’s durvalumab (IMFINZI®) can decrease tumor volume in patients with primary untreated locally...

Read More


Biothera Pharmaceuticals Presents Translational Data from Ongoing Clinical Trials Showing Imprime PGG in Combination with Merck’s KEYTRUDA® (pembrolizumab) Drives Innate and Adaptive Immune Responses in Tumors

EAGAN, MN — April 16, 2018 — Biothera Pharmaceuticals, Inc. today announced the presentation of new translational data from ongoing phase 2 clinical trials combining Biothera’s Imprime PGG with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed by Merck (known as MSD outside the United States and Canada).  These data provide the first evidence in human clinical trials that Imprime PGG-based therapy can activate the immune system...

Read More


Preclinical Data Showing Synergy of Biothera Pharmaceuticals’ Imprime PGG and a CD40 Agonist in a Pancreatic Cancer Model Presented at Keystone Symposia

EAGAN, MN — March 26, 2018 — Biothera Pharmaceuticals, Inc. and the Abramson Cancer Center of the University of Pennsylvania announced today the presentation of new preclinical data demonstrating the combination of Imprime PGG and a CD40 agonist antibody stimulated T cell-dependent anti-tumor activity in a pancreatic cancer model.  The data were presented at the ongoing Keystone Symposia Conference – Cancer Immunotherapy: Combinations in Montreal,...

Read More


Biothera Pharmaceuticals Commences Phase 2 Head and Neck Cancer Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)

Study Is Second Clinical Research Collaboration with Merck EAGAN, MN — February 6, 2018 — Biothera Pharmaceuticals, Inc. announced today that patient treatment has commenced in its Phase 2 clinical study in squamous cell carcinoma of the head and neck (SCCHN).  The research collaboration with Merck (known as MSD outside the United States and Canada) will evaluate Biothera’s Imprime PGG in combination with KEYTRUDA® (pembrolizumab),...

Read More


Biothera Pharmaceuticals Enters Cancer Immunotherapy Clinical Trial Collaboration Agreement

Phase 1b/2 clinical study in colorectal cancer to evaluate Imprime PGG in combination with PD-L1 immunotherapy and anti-VEGF therapy EAGAN, MN — November 28, 2017 — Biothera Pharmaceuticals, Inc. today announced that it has entered into a clinical trial collaboration agreement with Genentech, Inc., a member of the Roche Group, to assess the safety and efficacy of Biothera’s Imprime PGG in combination with Genentech’s atezolizumab...

Read More


Biothera Pharmaceuticals Presents Data Broadening Imprime PGG Mechanism of Action

Reduces expression of IDO, a potent suppressor of an anti-cancer T cell response Supplementation with IVIG boosts biomarker levels, restoring Imprime-driven pharmacodynamic responses EAGAN, MN — November 13, 2017 — Biothera Pharmaceuticals, Inc. announced today the presentation of clinical and preclinical research supporting the mechanism of action for the Company’s cancer immunotherapy Imprime PGG, which is currently being evaluated in combination with immune checkpoint inhibitor...

Read More


Biothera Pharmaceuticals Presents Preclinical Data Showing Imprime PGG Activates Natural Killer Cell-Mediated Tumor Killing

Data Presented at AACR-NCI-EORTC International Conference EAGAN, MN — October 30, 2017 — Biothera Pharmaceuticals, Inc. announced today the presentation of new preclinical findings showing that the Company’s Phase 2 cancer immunotherapy Imprime PGG activates Natural Killer (NK) cell-mediated killing of cancer cells. The data were presented at the ongoing AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, taking...

Read More


Biothera Announces Three Presentations at Upcoming American Association for Cancer Research Annual Meeting

EAGAN, MN — March 27, 2017 — Biothera Pharmaceuticals Inc. announced today that it will present three scientific posters at the American Association for Cancer Research (AACR) Annual Meeting April 1-5 in Washington, D.C. One poster was selected for the late-breaking session that highlights the newest and most exciting research. Poster Presentations: Session Date & Time:  Monday, April 3, 8:00 AM – 12:00 PM Eastern...

Read More


Biothera Pharmaceuticals’ Phase 2 Study of Imprime PGG Combination Therapy in Non-Small Cell Lung Cancer Patients Published in Investigational New Drugs

EAGAN, MN — March 24, 2017 — Biothera Pharmaceuticals, Inc. today announced peer-reviewed publication of results of a randomized Phase 2 clinical study of the Company’s cancer immunotherapy Imprime PGG in combination with Erbitux® (cetuximab) and chemotherapy in metastatic non-small cell lung cancer (NSCLC) patients. The study findings have been published online in the journal Investigational New Drugs. Completed by Biothera in 2013, the study was...

Read More


Biothera Pharmaceuticals Announces Presentation of Clinical Data Supporting Use of a Patient Selection Biomarker for its Phase 2 Cancer Immunotherapy

Clinical findings presented at the ASCO-SITC Clinical Immuno-Oncology Symposium EAGAN, MN — February 24, 2017 — Biothera Pharmaceuticals, Inc. will present data today from all cohorts (total N=36) enrolled in a healthy human volunteer study of Imprime PGG, the Company’s phase 2 cancer immunotherapy. The findings showed that administration of Imprime PGG to healthy human subjects results in immunopharmacodynamic (IPD) responses previously associated with the anti-tumor responses in...

Read More



Page 1 of 1112345...10...Last »